We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Munir
Pirmohamed
+44 (0)1517945549
munirp@liverpool.ac.uk
Dr
Mark
Goodall
None available
MGoodall@liverpool.ac.uk
Ms
Alison
Gummery
+44 (0)151 7959679
A.E.Gummery@liverpool.ac.uk
Dr
Sudeh
Cheraghi-Sohi
+44 (0) 161 275 7665
sudeh.cheraghi-sohi@manchester.ac.uk
Cardiovascular, renal and urogenital
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Almost a million people in the UK live with heart failure, most of whom also have kidney problems. This is because the heart and kidneys strongly affect each other. If the heart suddenly works less well, kidney function can worsen. Modern treatments help people with heart failure to live longer, healthier lives but the amount and type of their medication need to be checked regularly. Too low a dose of heart medication makes heart failure symptoms worse. Higher doses of heart medication can make kidney function worse. Either can lead to hospitalisation and increase the risk of death. At present, the frequency of blood tests to measure kidney function varies widely between GPs. Individuals respond differently to changes in medicines, and there is no way to work out how often a kidney blood test is required. If tests are not frequent enough, worsening kidney function might not be detected early, risking hospitalisation. Others might have more tests than needed, causing inconvenience.
The RENAL-HF programme involves a series of linked work packages which aim to improve kidney health in people living with heart failure by developing technology to predict how often each person with heart failure needs a kidney blood test and producing expert and consistent advice for GPs, nurses and pharmacists on how to adjust medicine dose and/or medicine type to keep both the heart and kidneys working together at their best. Work Package 2 (Stages 1-5) involves gathering the views of healthcare professionals, patients, and carers to ensure that the care pathway we develop is acceptable for patients and professionals and complements existing systems in GP practices. This work package aims to design a useful tool for patient benefit. Without this work package, we cannot design a useful tool for patient benefit. To ensure that we achieve this objective, the team plans to conduct surveys and interviews with GPs, nurses and pharmacists who work in GP practices to understand how the kidney health of people with heart failure is currently managed and combine the learning to create a list of components to include in the pathway to help improve guidelines for monitoring kidney health for people with heart failure. Key groups (including patients, GPs, nurses, pharmacists, specialists, and commissioners) will discuss and vote on these components to decide which ones are the most important. The RENAL-HF team, including members of the public, will work out what training would be most helpful to support GPs, nurses and pharmacists in managing the kidney health of people with heart failure and a group of GPs, nurses and pharmacists will be invited to test the new system for managing kidney health to make sure they are happy with how it works and that the instructions are clear and easy to use. This information will be used to help improve the system, and ready to test the feasibility and acceptability of the new care pathway (Stage 6).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Patient sample:1. People with heart failure who live outside of the UK. As the study initially focuses on developing a care pathway within England, we feel that our sample should reflect the experiences and views of patients currently living in England. 2. For patients recruited via a GP practice, we will ask practices to exclude patients with heart failure who:2.1. Lack of mental capacity as identified by the practice2.2. Are currently receiving inpatient treatment or admitted to the hospital for an exacerbation of their heart failure in the previous six weeks3. For patients recruited via other routes, we will exclude patients if they are unable to give valid consent, but we will not include capacity assessments in the study design
Professional sample:Professionals who work outside of England
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Prof
Munir
Pirmohamed
+44 (0)1517945549
munirp@liverpool.ac.uk
Dr
Mark
Goodall
None available
MGoodall@liverpool.ac.uk
Dr
Sudeh
Cheraghi-Sohi
+44 (0) 161 275 7665
sudeh.cheraghi-sohi@manchester.ac.uk
Ms
Alison
Gummery
+44 (0)151 7959679
A.E.Gummery@liverpool.ac.uk
The study is sponsored by University of Liverpool and funded by National Institute for Health and Care Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 54090
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
